Highly specific plasma β‐amyloid assays on the fully automated platform predict brain β‐amyloid pathology determined by a Centiloid threshold of amyloid PET

The U.S. Food and Drug Administration approved aducanumab for the treatment of Alzheimer’s disease (AD) under the accelerated approval pathway and several new drug candidates are currently in development or have been submitted for marketing authorization in the U.S. and other countries. Consequently, the necessity of pathological diagnosis of AD by confirming brain β‐amyloid (Aβ) pathology in routine clinical practice is increasing to ensure that appropriate AD patients can access these drugs. We reported the development of the fully automated plasma Aβ40 and Aβ42 immunoassays that showed high performance for predicting brain Aβ pathology defined by amyloid PET. Here, we present the effect of several markers on the performance of our plasma Aβ assays.